Notre Dame startup Structured Immunity and Medigene announce collaboration aimed at improving T cell receptor development
Structured Immunity, a Notre Dame startup and biotechnology company specializing in the optimization and validation of T cell receptor (TCR) proteins, and Medigene AG, a leading biotechnology company engaged in the development of immunotherapies for the treatment of cancer, today announced a research collaboration where Structured Immunity will provide structural immunology expertise in support of Medigene’s TCR discovery activities.